On October 20, Regeneron Pharmaceuticals rose 3.06% in Regular Trading, trading around $804.435 per share, with turnover of $39.0102 million.

The move was supported by a clear event catalyst: the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of an updated Libtayo dosing regimen across all approved European Union indications.

The recommendation supports 700 mg intravenous dosing every six weeks after an initial 12 weeks of 350 mg every three weeks, and also backs shortening the 350 mg infusion time to 15 to 30 minutes after a well-tolerated first 30-minute infusion. The update points to improved treatment convenience for patients and providers. A final decision from the European Commission is expected in the coming months. Earlier this month, UBS also upgraded the stock to buy and raised its price target to $978, adding supportive sentiment around the name.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)